Form 4: Prime Medicine 10% Owner and Director David Liu Purchases 21,000 Shares Under 10b5-1 Plan

David R. Liu, a 10% owner and director of Prime Medicine, Inc. (PRME), has acquired 21,000 shares of common stock for approximately $33,589.50, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David R. Liu, identified as both a Director and a 10% Owner of Prime Medicine, Inc. (PRME), purchased 21,000 shares of the company's common stock.
• The transaction occurred on June 11, 2025, at a weighted-average price of $1.5995 per share.
• The purchase price for these shares ranged from $1.53 to $1.67, inclusive.
• This acquisition was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Liu on March 3, 2025.
• Following this transaction, David R. Liu beneficially owns a total of 20,177,945 shares of Prime Medicine, Inc. common stock.
• An Exhibit 24, a Limited Power of Attorney, was filed, authorizing specific individuals to execute and file SEC forms on behalf of David Liu.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider (10% owner and director) purchasing shares, indicating strong confidence in the company's value and future. The transaction being under a 10b5-1 plan further suggests a deliberate, long-term investment decision.

Positives

• The purchase of 21,000 shares by a 10% owner and director, David R. Liu, signals strong insider confidence in Prime Medicine, Inc.'s future prospects.
• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-planned investment decision rather than a reaction to immediate market fluctuations.

Risks

• None mentioned in this filing, as Form 4 primarily reports insider transactions and does not typically detail company-specific risks.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025."
• "The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.67, inclusive."

Industry Context

This insider purchase by a director and significant owner in Prime Medicine, a biotechnology company, aligns with a general trend where insider buying can signal confidence in a company's long-term prospects, particularly in sectors like biotech that often require significant capital and have long development cycles.

Corporate Governance

Related Party Transactions

• The reported transaction is a direct purchase of common stock by David R. Liu, a director and 10% owner of Prime Medicine, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The insider purchase by a significant owner and director may instill greater confidence among existing and potential shareholders, signaling management's belief in the company's value.
• Employees: While not directly impacted, positive insider sentiment can indirectly boost employee morale and confidence in the company's stability and future.

Key Dates

Recommendation

Keywords

Prime Medicine, PRME, Insider Trading, Form 4, Stock Purchase, David Liu, 10b5-1 Plan, Biotechnology, Pharmaceuticals, SEC Filing